Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 5/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908136 | 0.83 | SOS1 (0.67) | NPC1MAPTRAB9ATP53SMN1; SMN2 | |
| SCHEMBL1514939 | 0.83 | SOS1 (0.67) | NPC1MAPTRAB9ATP53SMN1; SMN2 | |
| SCHEMBL23964195 | 0.77 | DRD3 (0.60) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL10566155 | 0.76 | DRD3 (0.60) | NPC1MAPTRAB9ASMN1; SMN2DRD3 | |
| SCHEMBL20964519 | 0.74 | CACNA1G (0.49) | NPC1MAPTRAB9ATP53SMN1; SMN2 | |
| SCHEMBL23964126 | 0.74 | DRD3 (0.51) | NPC1MAPTRAB9ATP53SMN1; SMN2 | |
| SCHEMBL23964258 | 0.74 | DRD3 (0.50) | NPC1MAPTRAB9ATP53SMN1; SMN2 | |
| SCHEMBL23964351 | 0.74 | DRD4 (0.49) | NPC1MAPTRAB9ADRD3DRD2 | |
| SCHEMBL23964197 | 0.74 | DRD3 (0.47) | NPC1MAPTRAB9ATP53SMN1; SMN2 | |
| SCHEMBL23964165 | 0.73 | DRD3 (0.49) | NPC1MAPTRAB9ADRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-09-07 | — | — | US | disclosed |
| EP-1586558-A2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors | G.D. Searle LLC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-04-01 | — | — | US | disclosed |
| US-6569882-B2 | Viricides; enzyme inhibitors | G. D. SEARLE & CO. | 2003-05-27 | — | — | US | disclosed |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-01-16 | — | — | US | disclosed |
| US-6143747-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0804428-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | NPC1 2211/4885MAPT 1422/4885RAB9A 941/4885 |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | PRSS1, DNPEP, PREP | NPC1 2193/4885MAPT 1389/4885RAB9A 1011/4885 |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | NPC1 2211/4885MAPT 1422/4885RAB9A 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.